Canopy Growth Corporation (CGC)
USD 2.83
(-7.21%)
USD 2.83
(-7.21%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.3 Billion USD | -46.69% |
| 2022 | 2.43 Billion USD | -56.56% |
| 2021 | 5.61 Billion CAD | -17.71% |
| 2020 | 6.82 Billion CAD | -0.5% |
| 2019 | 6.85 Billion CAD | -21.46% |
| 2018 | 8.73 Billion CAD | 507.72% |
| 2017 | 1.43 Billion CAD | 112.04% |
| 2016 | 677.6 Million CAD | 372.66% |
| 2015 | 143.36 Million CAD | 452.19% |
| 2014 | 25.96 Million CAD | 403.78% |
| 2013 | 5.15 Million CAD | 914.83% |
| 2012 | 507.81 Thousand CAD | -6.88% |
| 2011 | 545.34 Thousand CAD | -3.17% |
| 2010 | 563.21 Thousand CAD | -4.26% |
| 2009 | 588.3 Thousand CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 939.84 Million USD | -1.08% |
| 2023 Q4 | 959.9 Million USD | -29.41% |
| 2023 Q3 | 1.35 Billion USD | -18.49% |
| 2023 Q2 | 1.66 Billion USD | -23.84% |
| 2023 Q1 | 2.19 Billion USD | -10.19% |
| 2023 FY | 1.3 Billion USD | -46.69% |
| 2022 Q1 | 3.51 Billion CAD | -37.36% |
| 2022 FY | 2.43 Billion USD | -56.56% |
| 2022 Q4 | 2.43 Billion USD | -19.24% |
| 2022 Q3 | 3.02 Billion CAD | -11.23% |
| 2022 Q2 | 3.4 Billion CAD | -3.28% |
| 2021 Q3 | 6.3 Billion CAD | -2.8% |
| 2021 Q2 | 6.49 Billion CAD | -6.83% |
| 2021 Q4 | 5.61 Billion CAD | -11.0% |
| 2021 Q1 | 6.96 Billion CAD | 2.1% |
| 2021 FY | 5.61 Billion CAD | -17.71% |
| 2020 Q3 | 6.3 Billion CAD | -4.02% |
| 2020 Q1 | 6.84 Billion CAD | -0.17% |
| 2020 Q2 | 6.57 Billion CAD | -3.97% |
| 2020 FY | 6.82 Billion CAD | -0.5% |
| 2020 Q4 | 6.82 Billion CAD | 8.15% |
| 2019 Q4 | 6.85 Billion CAD | -14.77% |
| 2019 Q3 | 8.04 Billion CAD | -2.18% |
| 2019 Q1 | 8.64 Billion CAD | -0.99% |
| 2019 FY | 6.85 Billion CAD | -21.46% |
| 2019 Q2 | 8.22 Billion CAD | -4.86% |
| 2018 FY | 8.73 Billion CAD | 507.72% |
| 2018 Q4 | 8.73 Billion CAD | 1.06% |
| 2018 Q2 | 2.97 Billion CAD | 40.91% |
| 2018 Q3 | 8.64 Billion CAD | 190.28% |
| 2018 Q1 | 2.11 Billion CAD | 47.01% |
| 2017 Q2 | 798.68 Million CAD | 7.4% |
| 2017 Q4 | 1.43 Billion CAD | 31.2% |
| 2017 FY | 1.43 Billion CAD | 112.04% |
| 2017 Q1 | 743.66 Million CAD | 9.75% |
| 2017 Q3 | 1.09 Billion CAD | 37.12% |
| 2016 Q2 | 196.2 Million CAD | 28.88% |
| 2016 FY | 677.6 Million CAD | 372.66% |
| 2016 Q4 | 677.6 Million CAD | 141.43% |
| 2016 Q3 | 280.66 Million CAD | 43.05% |
| 2016 Q1 | 152.23 Million CAD | 6.19% |
| 2015 Q4 | 143.36 Million CAD | -4.14% |
| 2015 Q2 | 123.82 Million CAD | 148.86% |
| 2015 FY | 143.36 Million CAD | 452.19% |
| 2015 Q1 | 49.75 Million CAD | 4.15% |
| 2015 Q3 | 149.54 Million CAD | 20.78% |
| 2014 Q1 | 27.66 Million CAD | 91.17% |
| 2014 Q3 | 25.96 Million CAD | 2.36% |
| 2014 Q2 | 25.36 Million CAD | -8.31% |
| 2014 Q4 | 47.77 Million CAD | 84.01% |
| 2014 FY | 25.96 Million CAD | 403.78% |
| 2013 Q3 | 463.97 Thousand CAD | -7.35% |
| 2013 Q1 | 507.81 Thousand CAD | -0.63% |
| 2013 FY | 5.15 Million CAD | 914.83% |
| 2013 Q2 | 500.79 Thousand CAD | -1.38% |
| 2013 Q4 | 14.46 Million CAD | 3018.58% |
| 2012 Q4 | 511.05 Thousand CAD | -0.9% |
| 2012 FY | 507.81 Thousand CAD | -6.88% |
| 2012 Q1 | 545.34 Thousand CAD | 0.22% |
| 2012 Q2 | 532.69 Thousand CAD | -2.32% |
| 2012 Q3 | 515.69 Thousand CAD | -3.19% |
| 2011 Q4 | 544.13 Thousand CAD | -2.16% |
| 2011 FY | 545.34 Thousand CAD | -3.17% |
| 2011 Q1 | 563.21 Thousand CAD | 0.17% |
| 2011 Q2 | 564.39 Thousand CAD | 0.21% |
| 2011 Q3 | 556.14 Thousand CAD | -1.46% |
| 2010 Q2 | 581.39 Thousand CAD | -1.17% |
| 2010 FY | 563.21 Thousand CAD | -4.26% |
| 2010 Q4 | 562.22 Thousand CAD | -1.09% |
| 2010 Q3 | 568.42 Thousand CAD | -2.23% |
| 2010 Q1 | 588.3 Thousand CAD | 146.37% |
| 2009 FY | 588.3 Thousand CAD | 0.0% |
| 2009 Q4 | 238.78 Thousand CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Theratechnologies Inc. | 77.76 Million USD | -1572.042% |
| Harrow Health, Inc. | 311.75 Million USD | -317.1% |
| Dynavax Technologies Corporation | 997.09 Million USD | -30.412% |
| Biofrontera Inc. | 27.93 Million USD | -4555.342% |
| Cronos Group Inc. | 1.13 Billion USD | -14.642% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -8631.149% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | -176.036% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -2224.134% |
| RedHill Biopharma Ltd. | 23.04 Million USD | -5542.046% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | -1490.111% |
| Radius Health, Inc. | 1.71 Billion USD | 24.221% |
| Universe Pharmaceuticals INC | 53.28 Million USD | -2340.237% |
| DURECT Corporation | 45.18 Million USD | -2777.537% |
| ProPhase Labs, Inc. | 91.92 Million USD | -1314.525% |
| Safety Shot Inc | 12.7 Million USD | -10131.423% |
| Phibro Animal Health Corporation | 982.18 Million USD | -32.392% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -5522.549% |
| Alvotech | 950.09 Million USD | -36.864% |
| Assertio Holdings, Inc. | 286.41 Million USD | -353.996% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 7.711% |
| Rockwell Medical, Inc. | 52.17 Million USD | -2392.343% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -4654.934% |
| Procaps Group S.A. | 460.18 Million USD | -182.566% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | -78.544% |
| SCYNEXIS, Inc. | 128.41 Million USD | -912.623% |
| Aytu BioPharma, Inc. | 118.09 Million USD | -1001.088% |
| Viatris Inc. | 47.68 Billion USD | 97.273% |
| OptiNose, Inc. | 107.72 Million USD | -1107.038% |
| SIGA Technologies, Inc. | 254.83 Million USD | -410.261% |
| Tilray Brands, Inc. | 4.33 Billion USD | 70.006% |
| PetIQ, Inc. | 868.22 Million USD | -49.769% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -4654.934% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 60.007% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -10810.477% |
| Alimera Sciences, Inc. | 153.52 Million USD | -746.988% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | -13.734% |
| Silver Spike Investment Corp. | 88.57 Million USD | -1368.034% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -21747.911% |
| Organogenesis Holdings Inc. | 460.02 Million USD | -182.665% |
| Journey Medical Corporation | 76.84 Million USD | -1592.058% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | -3747.609% |
| Alpha Teknova, Inc. | 128.58 Million USD | -911.245% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | -4061.988% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | -375.09% |
| PainReform Ltd. | 9.93 Million USD | -12994.965% |
| Cosmos Health Inc. | 66.29 Million USD | -1861.413% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | -397.97% |
| TherapeuticsMD, Inc. | 43.3 Million USD | -2902.448% |
| Embecta Corp. | 1.21 Billion USD | -7.076% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -15310.02% |
| Talphera, Inc. | 20.39 Million USD | -6275.729% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 17.407% |
| Incannex Healthcare Limited | 17.04 Million USD | -7527.911% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -9715.635% |
| Shineco, Inc. | 84.17 Million USD | -1444.713% |
| Procaps Group, S.A. | 460.18 Million USD | -182.566% |
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | -43.775% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | -2164.673% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 21.247% |
| Alvotech | 950.09 Million USD | -36.864% |
| Hempacco Co., Inc. | 18.04 Million USD | -7106.807% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | -220.152% |
| Bright Green Corporation | 17.4 Million USD | -7371.852% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -531.854% |
| Kamada Ltd. | 351.96 Million USD | -269.444% |
| Indivior PLC | 1.95 Billion USD | 33.359% |
| Evoke Pharma, Inc. | 7.06 Million USD | -18296.004% |
| Flora Growth Corp. | 23.62 Million USD | -5403.809% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -9715.635% |
| Evolus, Inc. | 188.99 Million USD | -588.013% |
| HUTCHMED (China) Limited | 1.27 Billion USD | -1.606% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 14.051% |
| Akanda Corp. | 8.83 Million USD | -14609.627% |